<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/argenx-SE-ADR-US04016X1019">argenx SE ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/30/3284412/0/en/argenx-to-Report-First-Quarter-2026-Financial-Results-and-Business-Update-on-May-7-2026.html">argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/argenx-SE-ADR-US04016X1019">argenx SE ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/18/3276554/0/en/argenx-Brings-Neuromuscular-Leadership-to-AAN-2026-with-New-Data-Supporting-Broader-VYVGART-Use-Across-MG-and-CIDP.html">argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP</a>
    </div>

      <div class="me-0 me-md-5">
        ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART&#39;s approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports e...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/argenx-SE-ADR-US04016X1019">argenx SE ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260324819483/en/eClinical-Solutions-elluminate%C2%AE-Platform-Supports-argenx-to-Enhance-Data-Oversight-and-Efficiency/">eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency</a>
    </div>

      <div class="me-0 me-md-5">
        BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the elluminate Clinical Data Cloud® to improve and enhance clinical data processes. The elluminate platform is designed to improve access to and analysis of clinical trial data across sources with a c...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/argenx-SE-ADR-US04016X1019/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>